(RTTNews) - Sandoz, Inc., an unit of Novartis Pharma AG, is recalling one lot of deep vein thrombosis (DVT) medication Enoxaparin Sodium in the form of injection for the potential exposure to high ...
Patients exposed to a higher dose may be subject to bleeding complications. Apotex Corp announced the voluntary recall of 2 batches of Enoxaparin Sodium Injection ...
Princeton, NJ, Sandoz Inc. (“Sandoz”) is initiating a recall of one lot (SAB06761A, Exp 04/2023) of Enoxaparin Sodium Injection, USP 40 mg/0.4 mL Single-Dose Syringes to the consumer level. A portion ...
The prophylaxis of thromboembolic disorders (deep vein thrombosis) in patients undergoing: orthopedic surgery of the hip or knee; high-risk abdominal, gynecological, or urological surgeries; ...
July 26, 2010 — The US Food and Drug Administration (FDA) has approved the first generic formulation of enoxaparin sodium injection (Sandoz, Inc; brand name, Lovenox; Sanofi-Aventis US, LLC), a ...
Princeton, New Jersey, April 25, 2012 – Sandoz today announced the introduction of enoxaparin sodium injection, USP 3 mL vials, a generic version of Sanofi's Lovenox® Injection Multiple-Dose Vials, in ...
The Cabinet of Ministers granted approval for the resolutions furnished by the Minister of Health to award procurements based on the recommendations of the Standing Procurement Committee appointed by ...
The U.S. Food and Drug Administration today approved the first generic version of Lovenox (enoxaparin sodium injection), an anti-coagulant drug used to prevent deep vein thrombosis (DVT), a ...
Silver Spring, MD - The US Food and Drug Administration (FDA) has granted approval of the first generic formulation of enoxaparin (Lovenox, Sanofi-Aventis) sodium injection, a low-molecular-weight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback